

NCIC CLINICAL TRIALS GROUP

COMMITTEE ON ECONOMIC ANALYSIS (!)

AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: AUSTEN

APRIL 27, 2012 – 8:00 AM – 12:00 PM

CHAIRS: NICOLE MITTMANN AND NATASHA LEIGHL

8:00 am	Welcome	N. Mittmann / N. Leighl
8:10 am	Approval of Spring Meeting Minutes	All
8:15 am	Economic Data Compliance and Management	
	<ul style="list-style-type: none">• Compliance – Keyue Ding• Data Management – Penny Bradbury	
9:00 am	Methodologic Studies (incl ARCC, QoL Ctte)	N. Mittmann/N. Leighl/ J. Hoch/ All
9:45 am	Break	
10:00 am	Trial Update (Committees with asterisks have data to report, imminent final analysis, active secondary projects or an approved trial in development and will require 5-10 minutes. Other committees are expected to provide very brief updates of 2-3 minutes)	
	<ul style="list-style-type: none">• GI*• Breast site• Hematology*• GU site• Lung site*• Head and Neck*• Gynecology*• Brain site• Symptom Control	C.O'Callaghan L. Bordeleau M. Cheung N. Reaume N. Leighl A. Johnson N. Mittmann N. Mittmann J. Wu
11:00 am	Grant update, future directions	N. Mittmann/All
11:30 am	New Business	All
12:00 pm	Meeting Adjourned	

continued on next page ...

**Meeting Objectives with Reference to MOCOMP Credits
Committee on Economic Analysis**

1. To review the results of economic analyses of clinical trials in order to enhance understandings of the trials' results with respect to intervention adoption.
2. To enhance understandings of the methodologies of economic evaluations, specifically as these relate to the conduct and analyses of randomized controlled trials (RCTs).
3. To provide a focused analysis of the inclusion of utility assessments in the conduct of RCTs. This objective will be addressed both independently within the CEA and in collaboration with the QoL Committee.
4. To review how economic analyses may be best conceived and presented in grant applications.